Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHRONO-EVP: Time-of-day Dependent Administration of Enfortumab Vedotin and Pembrolizumab (EV/P) in Advanced Bladder Cancer

NCT07346053 is registered in ClinicalTrials.gov with Guliz Ozgun as lead sponsor.

NCT NCT07346053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07346053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHRONO-EVP: Time-of-day Dependent Administration of Enfortumab Vedotin and Pembrolizumab (EV/P) in Advanced Bladder Cancer
Lead sponsor
Guliz Ozgun
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2032
Enrollment
224 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bladder cancer